Latest studies
- Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaBulgaria - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerBulgaria - RecruitingPHASE2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This study is looking for adults with Graves' disease whose thyroid is overactive despite medication. It aims to see if a new medicine, IMVT-1402, is safe and helps control their thyroid better than a dummy medicine. We want to find a better treatment.
Graves' DiseaseBulgaria - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionBulgaria - Not yet recruitingPHASE3
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
This study looks at whether pregnant women at high risk of pre-eclampsia can safely stop taking low-dose aspirin earlier. It compares stopping aspirin at 24-28 weeks of pregnancy with continuing until 36 weeks, to see if shorter treatment is just as effective.
PreeclampsiaBulgaria - RecruitingPHASE2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
This study is looking into a new treatment called ABBV-142 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to check if the new drug is safe, what side effects it might cause, and if it helps improve the condition compared to a dummy drug.
Idiopathic Pulmonary FibrosisBulgaria - RecruitingPHASE3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
This study is testing a new medicine, depemokimab, for people with moderate to severe COPD that involves a specific type of inflammation. We want to see if starting this medicine early helps improve their breathing and reduce flare-ups.
Pulmonary Disease, Chronic ObstructiveBulgaria - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisBulgaria - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
Follicular Lymphoma (FL)Bulgaria - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerBulgaria - RecruitingPHASE2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
This study is looking at a medicine called eluxadoline to see if it can help children aged 6-17 with Irritable Bowel Syndrome (IBS) that causes diarrhoea. Researchers want to understand how it works in children, if it's safe, and how well it helps manage symptoms.
Irritable Bowel SyndromeBulgaria - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
Breast CancerBulgaria - RecruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
Generalized Myasthenia GravisBulgaria - RecruitingPHASE3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study looks at a new medicine, NNC0487-0111, for people with heart failure and obesity. It compares the medicine to a dummy treatment (placebo) to see if it's safe and helps improve heart health.
ObesityHeart FailureBulgaria - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
Carcinoma, Renal CellBulgaria - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Bulgaria - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisBulgaria - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaBulgaria - Active not recruitingPHASE3
Avelumab Program Rollover Study
This study is for people with solid tumours already receiving a cancer medicine called avelumab in another clinical trial. It aims to safely continue their treatment and closely watch for any side effects, ensuring they receive ongoing care.
Solid TumorsBulgaria - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
CancerBulgaria - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseBulgaria - Active not recruitingPHASE2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This study is checking if the benefits of bepirovirsen for Hepatitis B last over time. It's for people who previously took part in a bepirovirsen trial and showed good results. No new treatment is given in this follow-up study, just monitoring.
Hepatitis BBulgaria - Not yet recruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseBulgaria - RecruitingPHASE3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Duvakitug for people with Crohn's disease that isn't well controlled. It compares Duvakitug to a dummy medicine to see if it's safe and effective in improving symptoms for those with moderately to severely active Crohn's.
Crohn's DiseaseBulgaria - RecruitingPHASE3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
This study is testing a new medicine, Ris-Rez, for advanced small cell lung cancer that has come back. It aims to see if Ris-Rez works better than standard treatment (topotecan) to shrink tumours and help people live longer, while also checking its safety.
Neoplasms, LungBulgaria - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseBulgaria - RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
This study compares a new medicine, PF-08046054, with a standard lung cancer treatment, Docetaxel. It's for adults with a certain type of lung cancer that has already been treated and has a specific marker called PD-L1.
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung CarcinomaBulgaria - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseBulgaria - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
This study is testing a new medicine called empasiprubart for adults with a nerve condition called CIDP. It wants to see if the medicine is safe and helps people feel better. Participants will get the study medicine or a dummy medicine first, then everyone will get the study medicine.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating PolyradiculoneuropathyBulgaria - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
Ulcerative ColitisBulgaria - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Bulgaria - Active not recruitingPHASE3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
This study is testing a new drug called frexalimab for people with a type of multiple sclerosis (MS) called non-relapsing secondary progressive MS (nrSPMS). Researchers want to see if it can slow down MS progression and if it's safe. It's compared to a dummy drug (placebo).
Multiple SclerosisBulgaria - Active not recruitingPHASE3
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
This study looks at a new drug, capivasertib, combined with standard treatment (abiraterone and ADT) for men with prostate cancer that has spread and is sensitive to hormone treatment. It's for men whose cancer has a specific change called PTEN deficiency.
Hormone-Sensitive Prostate CancerBulgaria - Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
Diffuse Large B-cell LymphomaBulgaria - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Bulgaria - Active not recruitingPHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This study looks at a new drug, efgartigimod, for adults with CIDP, a nerve condition. It aims to see how safe and effective it is over a long time when given under the skin. Some participants might also try taking the drug less often.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Bulgaria - Active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
Limited Stage Small Cell Lung CancerSmall Cell Lung CancerBulgaria - Active not recruitingPHASE3
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
This study looks at a medicine called Bimekizumab for long-term safety and how well it works in people with a type of arthritis affecting the spine, including Ankylosing Spondylitis. It's for people who have already been in related Bimekizumab studies.
Axial SpondyloarthritisAnkylosing Spondylitisr-axSpaNr-axSpaBulgaria - Enrolling by invitationPHASE3
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study looks at the long-term safety and effects of a new drug called litifilimab for adults with certain types of lupus affecting the skin. It's for people who were in an earlier study and whose lupus didn't improve with usual treatments.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusBulgaria - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
Chronic Kidney DiseaseProteinuriaChildrenBulgaria - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseBulgaria - RecruitingPHASE3
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
This study is looking at a new medicine called Ribupatide for people living with obesity. It compares Ribupatide with another medicine, Semaglutide, and a dummy treatment, to see how well it helps with weight loss. We want to find out if Ribupatide is more effective and safe.
ObesityBulgaria - RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
This study is testing a new medicine, PF-07248144, with an existing one, fulvestrant, for advanced breast cancer that has grown despite previous treatment. It aims to see if this combination is safe and effective.
Breast CancerBulgaria - Active not recruitingPHASE3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
This study looks at a new medicine for adults with overweight or obesity and type 2 diabetes. It aims to see if the medicine helps with weight loss and is safe. The medicine is given as a weekly injection under the skin.
ObesityOverweight and/or ObesityOverweightDiabetes, Type 2Bulgaria - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVBulgaria - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
Diffuse Large B-Cell LymphomaBulgaria - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Bulgaria - RecruitingPHASE3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
This study looks at how safe and effective a medicine called mezagitamab is for adults with a bleeding condition called ITP. If you’ve been in a previous mezagitamab study, you might be invited to join this longer follow-up.
Immune Thrombocytopenic Purpura (ITP)Bulgaria - RecruitingPHASE3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
This study looks at a daily tablet called upadacitinib for severe alopecia areata, a condition where your immune system attacks hair follicles, causing hair loss. It aims to see how safe and effective it is for teenagers and adults.
Alopecia AreataBulgaria - RecruitingPHASE2
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
This study looks at a new medicine called osilodrostat (LCI699) for children and teenagers aged 2-17 with Cushing's syndrome. Researchers want to see how the medicine works in the body, its effects, and if it's safe. It's for those who have had surgery, are waiting for it, or can't have it right away.
Cushing SyndromeBulgaria